MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation and biosuperior antibodies, announced today that it has licensed its XmAb® and Xtend™ technology platforms to Centocor Research & Development, Inc. (“Centocor”) for the optimization of Centocor’s antibody drug candidates. The license follows a 2009 license agreement that gave Centocor access to Xencor’s proprietary Immunofilter™ software for the prediction of potential immunogenic sites in therapeutic proteins.
